ArticleJACC. Case reports2026
Native Valve Infective Endocarditis Caused by Staphylococcus condimenti: First Case Reported.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStaphylococcus condimenti is a coagulase-negative staphylococcus previously considered nonpathogenic. We report to our knowledge the first documented case of native-valve infective endocarditis caused by this pathogen. CASE SUMMARY: A 67-year-old man with rheumatic heart disease presented with fever and purpura. Initial IgA-dominant glomerulonephritis and leukocytoclastic vasculitis suggested systemic vasculitis. However, echocardiography revealed a large mitral vegetation. Scondimenti was identified by MALDI-TOF mass spectrometry and 16S rRNA sequencing from blood cultures and was subsequently confirmed by resected valve culture. After urgent mitral valve replacement and targeted cefazolin, the patient achieved full recovery and resolution of all immune-mediated complications. DISCUSSION: This report identifies Scondimenti as an emerging pathogen capable of significant valvular destruction and immune-mediated phenomena mimicking systemic vasculitis. TAKE-HOME MESSAGES: Rare coagulase-negative staphylococci require integrating clinical context and species-level molecular identification to avoid dismissal as contaminants. Emerging pathogens can present with misleading systemic immunological manifestations, requiring high clinical suspicion for infective endocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.